ACP
SNDX icon

Acuta Capital Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Acuta Capital Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-297,035
Closed -$4.31M – 55
2023
Q3 		$4.31M Sell
297,035
-2,806
-0.9% -$53.1K 2.89% 14
2023
Q2 		$6.28M Sell
299,841
-30,159
-9% -$628K 4.25% 5
2023
Q1 		$6.97M Buy
330,000
+5,386
+2% +$134K 5.13% 6
2022
Q4 		$8.26M Hold
324,614
– – 5.08% 7
2022
Q3 		$7.8M Buy
324,614
+119,611
+58% +$2.68M 3.36% 8
2022
Q2 		$3.94M Sell
205,003
-1,123
-0.5% -$18.7K 2.2% 15
2022
Q1 		$3.58M Hold
206,126
– – 1.67% 23
2021
Q4 		$4.51M Hold
206,126
– – 1.9% 16
2021
Q3 		$3.94M Hold
206,126
– – 1.39% 21
2021
Q2 		$3.54M Sell
206,126
-49,054
-19% -$898K 1.41% 25
2021
Q1 		$5.71M Sell
255,180
-210,320
-45% -$4.75M 2.06% 22
2020
Q4 		$10.4M Buy
465,500
+224,756
+93% +$4.66M 2.82% 13
2020
Q3 		$3.55M Hold
240,744
– – 0.96% 31
2020
Q2 		$3.57M Buy
+240,744
New +$3.67M 1.03% 33

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acuta Capital Partners's SNDX Position: Q4 2023 in Review

Acuta Capital Partners sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 297,035 shares — an estimated $4.31M sold.

Acuta Capital Partners first reported a position in SNDX in Q2 2020 and held it in 14 quarters. The position peaked at $10.4M in Q4 2020. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

  • Acuta Capital Partners reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 297,035 Syndax Pharmaceuticals shares in Q4 2023, an estimated $4.31M.
  • Acuta Capital Partners first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 14 quarters.
  • Acuta Capital Partners's Syndax Pharmaceuticals position peaked at $10.4M in Q4 2020.
  • 177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.